当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
The New England Journal of Medicine ( IF 70.670 ) Pub Date : 2019-09-19 , DOI: 10.1056/nejmoa1911303
John J V McMurray,Scott D Solomon,Silvio E Inzucchi,Lars Køber,Mikhail N Kosiborod,Felipe A Martinez,Piotr Ponikowski,Marc S Sabatine,Inder S Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Vijay K Chopra,Rudolf A de Boer,Akshay S Desai,Mirta Diez,Jaroslaw Drozdz,Andrej Dukát,Junbo Ge,Jonathan G Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta E A Ljungman,Béla Merkely,Jose C Nicolau,Eileen O'Meara,Mark C Petrie,Pham N Vinh,Morten Schou,Sergey Tereshchenko,Subodh Verma,Claes Held,David L DeMets,Kieran F Docherty,Pardeep S Jhund,Olof Bengtsson,Mikaela Sjöstrand,Anna-Maria Langkilde,

BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. METHODS In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. RESULTS Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups. CONCLUSIONS Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).
更新日期:2019-11-21

 

全部期刊列表>>
向世界展示您的会议墙报和演示文稿
全球疫情及响应:BMC Medicine专题征稿
欢迎探索2019年最具下载量的化学论文
新版X-MOL期刊搜索和高级搜索功能介绍
化学材料学全球高引用
ACS材料视界
南方科技大学
x-mol收录
南方科技大学
自然科研论文编辑服务
西湖大学
中国科学院长春应化所于聪-4-8
武汉工程大学
课题组网站
X-MOL
深圳大学二维材料实验室张晗
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug